Cancer Drug Parity Act of 2021
Summary
Cancer Drug Parity Act of 20 21 This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration. To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.
Bill status
in committee
1 of 4 stages cleared
Introduction
Oct 2021
Committee Review
Floor Vote
President
Introduced Oct 27, 2021
Last action Oct 27, 2021
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Oct 27, 2021
Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
upper
Oct 27, 2021
Introduced
Introduced in Senate
upper
1 primary · 21 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Tina Smith
DDemocratic
Co
Amy Klobuchar
DDemocratic
Co
Angus S. King, Jr.
IIndependent
Co
Christopher Murphy
DDemocratic
Co
Cindy Hyde-Smith
RRepublican
Co
Dianne Feinstein
DDemocratic
Co
Edward J. Markey
DDemocratic
Co
Jack Reed
DDemocratic
Co
Jeff Merkley
DDemocratic
Co
Jerry Moran
RRepublican
Co
John Boozman
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about S 3080
Scope: US
Hi! I can help you understand S 3080. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline